Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an open-market sale of 379 shares of common stock at $9.45 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. After this small sale, he directly holds 61,902 shares.
The footnotes note that the 379 shares sold had been acquired on May 29, 2026 through an employee stock purchase program, indicating this filing reflects routine, pre-planned portfolio activity rather than a large discretionary transaction.
VIR submitted a Form 144 notice relating to proposed sales of Common Stock. The filing lists 379 shares acquired under the ESPP on 05/29/2026 (cash purchase) and shows a prior sale by Brent Sabatini on 03/23/2026 involving 7,711 shares for $70,324.32. The filing date appears as 06/01/2026 and the broker listed is Fidelity Brokerage Services LLC.
Vir Biotechnology director Charles Elliott Sigal reported equity awards and updated holdings. He received 8,000 restricted stock units under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received stock options for 16,000 shares at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 39,806 shares of common stock directly and 10,000 shares indirectly through Sigal Family Investments, LLC, for which he disclaims beneficial ownership beyond his economic interest.
Vir Biotechnology, Inc. director Janet Napolitano reported awards of company equity as part of compensation. She received 8,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Equity Incentive Plan. These RSUs will vest in full on May 27, 2027, meaning the shares become fully owned at that time.
She was also granted a stock option for 16,000 shares of Common Stock with an exercise price of $9.10 per share. The option will vest and become exercisable in full on May 27, 2027. Following the RSU grant, Napolitano directly holds 24,416 shares of Vir Biotechnology common stock, and holds the newly granted option covering 16,000 shares.
Vir Biotechnology, Inc. director Robert J. More reported equity awards and updated his holdings. He received 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following these awards, he directly holds 48,656 shares of common stock and 16,000 option shares. An additional 509,917 shares are held for the benefit of Alta Partners NextGen Fund I, L.P.; More may be deemed to beneficially own these through his role with its general partner but disclaims beneficial ownership except for his pecuniary interest.
Vir Biotechnology, Inc. director Jeffrey S. Hatfield reported receiving new equity compensation. He acquired 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following the RSU grant, he holds 39,806 shares of common stock directly. These awards are compensation-related grants rather than open-market purchases or sales.
Vir Biotechnology director Ramy Farid reported routine equity compensation awards. He received 8,000 shares of Common Stock as restricted stock units under the company’s equity incentive plan, bringing his direct holdings to 32,000 shares after the grant.
He was also granted a stock option for 16,000 shares of Common Stock at an exercise price of $9.10 per share. Both the RSUs and the option are scheduled to vest in full on May 27, 2027, and the option expires on May 26, 2036. These are compensation-related acquisitions, not open-market purchases.
Vir Biotechnology director Norbert W. Bischofberger reported equity awards rather than open-market trades. He received 8,000 shares in the form of restricted stock units granted under Vir Biotechnology’s Equity Incentive Plan, which will vest in full on May 27, 2027. He was also granted a stock option covering 16,000 shares of common stock at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 21,333 shares of common stock directly and 10,667 shares indirectly through Nextquest, LLC, where he is a managing member.
Vir Biotechnology, Inc. reported governance updates and voting results from its 2026 Annual Meeting of Stockholders. Director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, citing a business conflict and no disagreement with the company. Robert More was appointed Audit Committee Chair and the Board size was reduced from eight to seven members. Stockholders elected three Class I directors to serve until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.